3 days Ago By ABMN Staff
Tarsus Pharmaceuticals ( NASDAQ:TARS – Free Report ) had its target price hoisted by The Goldman Sachs Group from $36.00 to $41.00 in a research report sent to investors on Friday morning, Benzinga reports.
The brokerage currently has a neutral rating on the stock. TARS has been the topic of a number of other reports. Oppenheimer lifted their price objective on Tarsus Pharmaceuticals from $63.
00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, November 14th. William Blair raised Tarsus Pharmaceuticals to a “strong-buy” rating in a research note on Friday, August 30th.
One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $54.20.
View Our Latest Stock Analysis on Tarsus Pharmaceuticals Tarsus Pharmaceuticals Stock Performance Hedge Funds Weigh In On Tarsus Pharmaceuticals A number of large investors have recently modified their holdings of the company. Quest Partners LLC bought a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at $61,000. Canada Pension Plan Investment Board bought a new position in shares of Tarsus Pharmaceuticals in the second quarter valued at approximately $114,000.
Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Tarsus Pharmaceuticals by 33.4% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock worth $166,000 after buying an additional 1,530 shares in the last quarter.
FMR LLC lifted its stake in Tarsus Pharmaceuticals by 236.6% during the 3rd quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after acquiring an additional 3,537 shares in the last quarter.
Finally, Dark Forest Capital Management LP bought a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter worth $202,000. 90.01% of the stock is currently owned by institutional investors.
Tarsus Pharmaceuticals Company Profile ( Get Free Report ) Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. See Also Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
